Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.

Original title: “Alnylam hops on AI train with up to $2B Inceptive partnership”

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

Original title: “A Spanish biotech banks $87M to make differentiated ADCs”

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.

Original title: “NewLimit’s $435M megaround; Lilly’s busy dealmaking week”

NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells.

Original title: “NewLimit snags $435M after seeing age reversal in human liver cells”

Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari.

Original title: “Travere beefs up rare kidney disease portfolio with up to $1.1B China deal”

Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its nonstop deal streak, including with Chinese biotechs; and looking ahead to this weekend’s American Diabetes Association meeting.

Original title: “ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck”

From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping them up at night.

Original title: “Facing pressure from China, BioSpace’s NextGen biotech leaders say: ‘Bring it on’”

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals.

Original title: “No longer a bargain pool, Chinese biotechs command higher premiums”

The forecast makes pharma one of the fastest-growing manufacturing industries in the U.S.

Original title: “Pharma manufacturing projected to create 19,000 jobs through 2034”

Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.

Original title: “Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug”

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.

Original title: “ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come”

Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.

Original title: “ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off”

A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.

Original title: “AbiVax falls as safety worries cloud ‘landmark’ immune drug results”

Fulcrum Therapeutics’ is down more than 50% Tuesday morning as the biotech discontinues development of its lead asset. Ipsen’s Tazverik, which belongs to the same class, was pulled from the market in March due to the risk of secondary malignancies.

Original title: “Fulcrum tanks as cancer concerns stymie sickle cell asset, trigger business reorg”

Eli Lilly and the Haisco Pharmaceutical Group have yet to disclose what specific indications they plan to prioritize.

Original title: “Lilly bets $3B+ to add China’s Haisco to growing list of partners in five-program pact”